公开(公告)号：US20240245514A1

公开(公告)日：2024-07-25

申请号：US18436900

申请日：2024-02-08

申请人： Howmedica Osteonics Corp.

发明人： Sonny Sheth ,  David Arazawa ,  j. Brook Burley ,  Sarah Elizabeth Smith ,  Matthew B. Havener ,  James San Antonio ,  Marc Gilles Long

IPC分类号： A61F2/28 ,  A61F2/30 ,  A61F2/46 ,  A61L27/02 ,  A61L27/26 ,  A61L27/36 ,  A61L27/40 ,  A61L31/00 ,  A61L31/12 ,  A61L31/16

CPC分类号： A61F2/28 ,  A61F2/30767 ,  A61F2/4601 ,  A61L27/02 ,  A61L27/025 ,  A61L27/3645 ,  A61L27/365 ,  A61L27/40 ,  A61L31/005 ,  A61L31/127 ,  A61L31/16 ,  A61F2002/2835 ,  A61F2002/3006 ,  A61F2002/30062 ,  A61F2002/3093 ,  A61F2/30965 ,  A61L27/26 ,  A61L2420/02 ,  A61L2420/06 ,  C12N2533/18

摘要： A bioactive filamentary structure includes a sheath coated with a mixture of synthetic bone graft particles and a polymer solution forming a scaffold structure. In forming such a structure, synthetic bone graft particles and a polymer solution are applied around a filamentary structure. A polymer is precipitated from the polymer solution such that the synthetic bone graft particles and the polymer coat the filamentary structure and the polymer is adhered to the synthetic bone graft particles to retain the graft particles.

公开(公告)号：US20180177923A1

公开(公告)日：2018-06-28

申请号：US15902063

申请日：2018-02-22

申请人： CorMatrix Cardiovascular, Inc.

发明人： Robert G. Matheny

IPC分类号： A61L27/54 ,  A61L27/36 ,  A61K31/7088 ,  A61K31/726 ,  A61K35/22 ,  A61K35/34 ,  A61K35/37 ,  A61K35/38 ,  A61K35/407 ,  A61K35/50 ,  A61L27/58 ,  A61L27/40 ,  A61L27/38 ,  A61L27/22 ,  A61K48/00 ,  A61K38/39 ,  A61K38/18 ,  A61K38/17 ,  A61K35/545 ,  A61K9/00

CPC分类号： A61L27/54 ,  A61K9/0019 ,  A61K31/7088 ,  A61K31/726 ,  A61K35/22 ,  A61K35/34 ,  A61K35/37 ,  A61K35/38 ,  A61K35/407 ,  A61K35/50 ,  A61K35/545 ,  A61K38/1741 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/39 ,  A61K48/00 ,  A61L27/227 ,  A61L27/3629 ,  A61L27/3633 ,  A61L27/367 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3834 ,  A61L27/3873 ,  A61L27/40 ,  A61L27/58 ,  A61L2300/412 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/45 ,  A61L2300/64 ,  A61L2400/06 ,  A61L2430/20 ,  A61L2430/30

摘要： Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

公开(公告)号：US20170340770A1

公开(公告)日：2017-11-30

申请号：US15678892

申请日：2017-08-16

申请人： InnoTERE GmbH

发明人： Berthold NIES

IPC分类号： A61L24/00 ,  A61K6/00 ,  A61L24/02 ,  A61K6/06 ,  A61L27/40

CPC分类号： A61L24/0084 ,  A61K6/0008 ,  A61K6/0023 ,  A61K6/0067 ,  A61K6/0643 ,  A61K6/0675 ,  A61L24/02 ,  A61L27/40 ,  A61L2430/02 ,  C08L71/02 ,  C08L33/08

摘要： The invention relates to implant materials that are based on hydraulic cements in the form of one or more pastes, suspensions or dispersions that contain mineral and/or organic and/or organomineral solids and that react, when combined or when reacted with an aqueous liquid, to a solid in a cement-type initiation reaction. The invention also relates to the use of these materials as technical, medical-technical and/or pharmaceutical products, especially as bone cements, bone replacement materials, bone glues, dental filling materials and implantable active ingredient carriers. The implant materials according to the invention in the form of one or more pastes, suspensions or dispersions that contain mineral and/or organic and/or organomineral solids are formulated in an excipient liquid in such a manner that the pastes, suspensions or dispersions are stable in storage at normal conditions over a prolonged period of time and that they react, when combined with an aqueous liquid or when added to an aqueous liquid, in a cement-type initiation reaction and set to a solid. The excipient liquid of the mineral paste, suspension or dispersion is substantially water-free, and water immiscible or insoluble or hardly soluble in water in the chemical sense.

公开(公告)号：US09770531B2

公开(公告)日：2017-09-26

申请号：US14767432

申请日：2014-02-10

申请人： CARTIHEAL (2009) LTD.

发明人： Nir Altschuler

IPC分类号： A61K36/00 ,  A61L27/36 ,  A61L27/52 ,  A61L27/54 ,  A61L27/56 ,  A61L27/12 ,  A61L27/20 ,  A61L27/40 ,  C01B25/32 ,  C01F11/18 ,  G01N1/00 ,  A61L27/50 ,  A61F2/28 ,  A61F2/30 ,  A61L27/38

CPC分类号： A61L27/3608 ,  A61F2/28 ,  A61F2/30 ,  A61F2/30756 ,  A61F2230/0006 ,  A61F2230/0065 ,  A61F2230/0067 ,  A61F2230/0069 ,  A61F2230/0071 ,  A61F2230/0086 ,  A61L27/12 ,  A61L27/20 ,  A61L27/3604 ,  A61L27/3637 ,  A61L27/365 ,  A61L27/3654 ,  A61L27/3834 ,  A61L27/40 ,  A61L27/50 ,  A61L27/52 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/112 ,  A61L2300/41 ,  A61L2300/412 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2430/02 ,  A61L2430/06 ,  C01B25/32 ,  C01F11/18 ,  C01P2006/90 ,  G01N1/00

摘要： This invention provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrates comprise a marine organism skeletal derivative and are characterized by a specific fluid uptake capacity value of less than 40%, processes for selection of the same and applications of the same. This invention also provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrates are characterized by having a contact angle value of more than 60 degrees, when in contact with a fluid. This invention also provides solid substrates for mitigating or preventing cell or tissue adherence and/or vascularization, which solid substrate is characterized by a minimal surface roughness (Ra) or substantial surface smoothness, as measured by scanning electron microscopy or atomic force microscopy. The invention also provides processes for selection of an optimized coral-based solid substrate.

公开(公告)号：US09737423B2

公开(公告)日：2017-08-22

申请号：US14733707

申请日：2015-06-08

申请人： TERUMO KABUSHIKI KAISHA

发明人： Kazuhiro Maruyama ,  Noboru Saito ,  Hiroki Goto

IPC分类号： A61F2/06 ,  A61F2/89 ,  A61L31/10 ,  A61L31/16 ,  A61F2/915 ,  A61L27/54 ,  A61L27/40 ,  A61F2/82 ,  B05B13/02

CPC分类号： A61F2/89 ,  A61F2/06 ,  A61F2/82 ,  A61F2/915 ,  A61F2002/91516 ,  A61F2002/9155 ,  A61F2002/91558 ,  A61F2002/91575 ,  A61F2002/91583 ,  A61F2210/0076 ,  A61F2230/0006 ,  A61F2230/0069 ,  A61F2240/001 ,  A61F2250/0026 ,  A61F2250/0029 ,  A61F2250/003 ,  A61F2250/0031 ,  A61F2250/0036 ,  A61F2250/0037 ,  A61F2250/0041 ,  A61F2250/0067 ,  A61F2310/00017 ,  A61F2310/00023 ,  A61F2310/00035 ,  A61F2310/00059 ,  A61F2310/00149 ,  A61F2310/00155 ,  A61F2310/00389 ,  A61F2310/0097 ,  A61L27/40 ,  A61L27/54 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/00 ,  A61L2420/08 ,  B05B13/0235 ,  C08L67/04

摘要： A stent able to minimize occurrences of strain and stress concentration in a drug coat layer upon expansive deformation of the stent in a radial direction to avoid the possibility of the drug separating from the stent, includes a stent body and a drug coating layer coated on the outside surface of the stent body so that the thickness of the drug coating layer gradually decreases toward a bent portion of the stent.

公开(公告)号：US20170112965A1

公开(公告)日：2017-04-27

申请号：US15354236

申请日：2016-11-17

申请人： ACell, Inc.

发明人： Rodney W. BOSLEY, JR. ,  Clay Fette ,  Robert S. Tullius

IPC分类号： A61L27/36 ,  A61L27/54 ,  A61L27/58

CPC分类号： A61L27/3633 ,  A61K9/14 ,  A61K9/16 ,  A61K35/12 ,  A61L27/26 ,  A61L27/40 ,  A61L27/50 ,  A61L27/54 ,  A61L27/58 ,  A61L2430/26 ,  A61L2430/34 ,  C08L89/00

摘要： Disclosed are tissue graft compositions made of particles having different densities, methods of making these compositions, and methods of using these compositions for promoting tissue restoration in a patient.

公开(公告)号：US20170014481A1

公开(公告)日：2017-01-19

申请号：US15211965

申请日：2016-07-15

申请人： BioMimetic Therapeutics, LLC

发明人： Samuel E. Lynch

IPC分类号： A61K38/18 ,  A61L27/58 ,  A61L27/54 ,  A61L27/56 ,  A61L27/12

CPC分类号： A61L27/54 ,  A61F2/28 ,  A61F2002/2835 ,  A61F2210/0004 ,  A61K9/0063 ,  A61K38/1858 ,  A61L27/025 ,  A61L27/12 ,  A61L27/227 ,  A61L27/24 ,  A61L27/40 ,  A61L27/425 ,  A61L27/56 ,  A61L27/58 ,  A61L2300/414 ,  A61L2400/06 ,  A61L2430/02 ,  A61L2430/06 ,  A61L2430/10 ,  A61L2430/12

摘要： A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

公开(公告)号：US09295758B2

公开(公告)日：2016-03-29

申请号：US14193008

申请日：2014-02-28

申请人： CORMATRIX CARDIOVASCULAR, INC.

发明人： Robert G Matheny

IPC分类号： A61L27/36 ,  A61L27/54 ,  A61K35/38 ,  A61K35/34 ,  A61K48/00 ,  A61L27/38 ,  A61L27/40 ,  A61K38/17 ,  A61K38/18 ,  A61K35/545 ,  A61K31/726 ,  A61K31/7088 ,  A61K35/37 ,  A61K35/407 ,  A61K35/22 ,  A61K38/39 ,  A61L27/58 ,  A61K35/50 ,  A61K9/00

CPC分类号： A61L27/54 ,  A61K9/0019 ,  A61K31/7088 ,  A61K31/726 ,  A61K35/22 ,  A61K35/34 ,  A61K35/37 ,  A61K35/38 ,  A61K35/407 ,  A61K35/50 ,  A61K35/545 ,  A61K38/1741 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/39 ,  A61K48/00 ,  A61L27/227 ,  A61L27/3629 ,  A61L27/3633 ,  A61L27/367 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3834 ,  A61L27/3873 ,  A61L27/40 ,  A61L27/58 ,  A61L2300/412 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/45 ,  A61L2300/64 ,  A61L2400/06 ,  A61L2430/20 ,  A61L2430/30

摘要： Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

公开(公告)号：US09265800B2

公开(公告)日：2016-02-23

申请号：US14619987

申请日：2015-02-11

申请人： MiMedx Group, Inc.

发明人： John Daniel

IPC分类号： A61L27/36 ,  A61K35/50 ,  A61L27/40 ,  A61J1/00 ,  A61L27/54 ,  A61L27/58 ,  A61F2/02 ,  A61L27/50 ,  B65D25/20 ,  B65D81/18 ,  B65D85/00

CPC分类号： A61K35/50 ,  A61F2/02 ,  A61J1/00 ,  A61L27/3604 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3691 ,  A61L27/3695 ,  A61L27/40 ,  A61L27/50 ,  A61L27/54 ,  A61L27/58 ,  A61L2300/412 ,  A61L2300/60 ,  A61L2300/64 ,  A61L2430/40 ,  B65D25/205 ,  B65D81/18 ,  B65D85/70

摘要： A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.

公开(公告)号：US20160038644A1

公开(公告)日：2016-02-11

申请号：US14269874

申请日：2014-05-05

申请人： Robert G. Matheny

发明人： Robert G. Matheny

IPC分类号： A61L27/54 ,  A61L27/22 ,  A61L27/36

CPC分类号： A61L27/54 ,  A61K9/0019 ,  A61K31/7088 ,  A61K31/726 ,  A61K35/22 ,  A61K35/34 ,  A61K35/37 ,  A61K35/38 ,  A61K35/407 ,  A61K35/50 ,  A61K35/545 ,  A61K38/1741 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/39 ,  A61K48/00 ,  A61L27/227 ,  A61L27/3629 ,  A61L27/3633 ,  A61L27/367 ,  A61L27/3683 ,  A61L27/3687 ,  A61L27/3834 ,  A61L27/3873 ,  A61L27/40 ,  A61L27/58 ,  A61L2300/412 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2300/45 ,  A61L2300/64 ,  A61L2400/06 ,  A61L2430/20 ,  A61L2430/30

摘要： Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.